IL10 and relapsing-remitting multiple sclerosis: FTY720 treatment inhibited Th1‐like Tregs in vivo, and Tregs isolated from FTY720‐treated RRMS patients produced significantly less IFNγ and downregulated T‐bet expression, whilst no changes were observed in FOXP3 and IL‐10 protein levels (Figure 5A).